Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formulation Pharmacokinetics Study of EPI-589 (DA350102)
jRCT2071220047Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of EPI-589 in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Pharmacokinetic parameters of EPI-589 and Safety and tolerability. Started Aug 2022; status: completed.
02
Drugs
EPI-589
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2071220047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220047.